AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -6.2% according to Deutsche.Deutsche set a target price of 9,500 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -5.4% according to Deutsche.Deutsche set a target price of 9,500 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 24.6% according to JP Morgan Cazenove.JP Morgan Cazenove set a target price of 12,500 GBX for the company, which..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 21.2% according to Jefferies.Jefferies set a target price of 12,500 GBX for the company, which when compared to the..
AstraZeneca plc (LON:AZN) and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 23.5% according to Jefferies.Jefferies set a target price of 12,500 GBX for the company, which when compared to the..
AstraZeneca plc (LON:AZN) has entered into a definitive agreement to acquire Icosavax, Inc. (NASDAQ: ICVX), a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein..
AstraZeneca plc (LON:AZN) has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma (sodium zirconium cyclosilicate). The decision was made due to substantially increased enrolment timelines..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 31.9% according to Barclays.Barclays set a target price of 13,500 GBX for the company, which when compared to the..
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast..
AstraZeneca plc (LON:AZN) has announced its 9M and Q3 2023 results. Revenue and EPS summary 9M 2023 Q3 2023 % Change % Change $m Actual CER[1] $m Actual ..
